Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial

Authors: Pignot, G., Fendler, J.P., Guy, L., Verhoest, G., Mottet, N., Doerfler, A., Abadie-Lacourtoisie, S., Azzouzi, A., Mongiat, P., Geoffrois, L., Eschwege, P., Di Fiore, F., Roubaud, G., Hoepffner, J.L., Barthelemy, P., Lang, H., Voog, E., Mandron, E., Tourani, J.M., Serrrate, C., Colau, A., Saldana, C., de La Taille, A., Nguyen, T., Kleinclauss, F., Loriot, Y., Irani, J., Eymard, J.C., Larre, S., Huillard, O., Zerbib, M., Rolland, F., Rigaud, J., Houede, N., Droupy, S., Malouf, G., Roupret, M., Vieillot, S., Letang, N., Lharidon, T., Gaschignard, N., Hilgers, W., Davin, J.L., Groeneveld, C.S. ^{1, 2}, Pfister, C. ^{3, 4}, Culine, S. ⁵, Harter, V. ⁶, Krucker, C. ¹, Fontugne, J. ^{1, 7}, Dixon, V. ¹, Sirab, N. ¹, Bernard-Pierrot, I. ¹, de Reyniès, A. ², Radvanyi, F. ¹, Allory, Y. ^{1, 7, ∗}

Source: In Annals of Oncology January 2025 36(1):89-98

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

Authors: Rosenberg, J.E. ^{1, ∗}, Galsky, M.D. ², Powles, T. ³, Petrylak, D.P. ⁴, Bellmunt, J. ⁵, Loriot, Y. ⁶, Necchi, A. ⁷, Hoffman-Censits, J. ⁸, Perez-Gracia, J.L. ⁹, van der Heijden, M.S. ¹⁰, Dreicer, R. ¹¹, Durán, I. ^{12, †}, Castellano, D. ¹³, Drakaki, A. ¹⁴, Retz, M. ¹⁵, Sridhar, S.S. ¹⁶, Grivas, P. ^{17, ‡}, Yu, E.Y. ¹⁸, O’Donnell, P.H. ¹⁹, Burris, H.A. ²⁰, Mariathasan, S. ²¹, Shi, Y. ²¹, Goluboff, E. ²¹, Bajorin, D. ¹

Source: In ESMO Open December 2024 9(12)

ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

Authors: Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B.P., Ravaud, A., Shariat, S.F., Szabados, B., van der Heijden, M.S., Gillessen, S.

Source: In Annals of Oncology June 2024 35(6):485-490

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Authors: Loriot, Y., Petrylak, D.P., Rezazadeh Kalebasty, A., Fléchon, A., Jain, R.K., Gupta, S., Bupathi, M., Beuzeboc, P., Palmbos, P., Balar, A.V., Kyriakopoulos, C.E., Pouessel, D., Sternberg, C.N., Tonelli, J., Sierecki, M., Zhou, H., Grivas, P., Barthélémy, P., Tagawa, S.T.

Source: In Annals of Oncology April 2024 35(4):392-401

Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201

Authors: Necchi, A., Pouessel, D., Leibowitz, R., Gupta, S., Fléchon, A., García-Donas, J., Bilen, M.A., Debruyne, P.R., Milowsky, M.I., Friedlander, T., Maio, M., Gilmartin, A., Li, X., Veronese, M.L., Loriot, Y.

Source: In Annals of Oncology February 2024 35(2):200-210

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Authors: Bastick, Patricia, Sewak, Sanjeev, Tran, Ben, Pichler, Martin, Shariat, Shahrokh, Rottey, Sylvie, Schatteman, Peter, Schrijvers, Dirk, Verschaeve, Vincent, Vulsteke, Christof, Barros Leite Ferreira, Luiza Aleixo, de Santana Gomes Andrea Juliana, Pereira, Junior, Joao Antonio, Azevedo, Sergio, Bastos, Diogo, Borges, Giuliano, Dettino, Aldo, Antonio, Pires Luis, Luz, Murilo, Martins, Suelen, Mota, Jose Mauricio, Toledo, Joseane, Eigl, Bernhard, Finch, Daygen, Gingerich, Joel, Dong, Haiying, Huang, Jian, Jin, Jie, Pan, Hongming, Sun, Zhongquan, Tian, Ye, Wan, Ben, Wu, Bin, Xu, Ting, Xue, Wei, Zhou, Fangjian, Barthelemy, Philippe, Borchiellini, Delphine, Calcagno, Fabien, Carnot, Aurelien, Cornillon, Pierre, Delva, Remy, Emambux, Sheik, Houede, Nadine, Laguerre, Brigitte, Lauridant, Géraldine, Loriot, Yohann, Mahammedi, Hakim, Maillet, Denis, Pouessel, Damien, Roubaud, Guilhem, Schlurmann-Constans, Friederike, Tosi, Diego, Zanetta, Sylvie, Banek, Severine, Feyerabend, Susan, Kramer, Mario, Niegisch, Guenther, Nuhn, Philipp, Schnabel, Marco, Wuelfing, Christian, Baka, Sofia, Bamias, Aristotelis, Fountzilas, George, Kalofonos, Harabolos, Karalis, Konstantinos, Kotsakis, Athanasios, Timotheadou, Eleni, Landherr, Laszlo, Mangel, Laszlo, Pe’er, Avivit, Levratovsky, Meital, Basso, Umberto, Battelli, Nicola, Cavo, Alessia, De Giorgi, Ugo, Doni, Laura, Galli, Luca, Gigante, Maria Olga, Guadalupi, Valentina, Maio, Michele, Milesi, Laura, Nolè, Franco, Scagliotti, Giorgio, Tortora, Giampaolo, Fukasawa, Satoshi, Harabayashi, Toru, Kamiya, Naoto, Kawahara, Takashi, Kawakita, Mutsushi, Matsubara, Nobunaki, Matsumoto, Kazumasa, Nishimura, Kazuo, Rikiya, Taoka, Shimizu, Nobuaki, Tagaki, Toshio, Kang, Taek Won, Kim, Jwa Hoon, Kim, SeHyun, Lee, Hyo Jin, Lee, Yun-Gyoo, Rha, Sun Young, Seo, Ho Kyung, Los, Maartje, Zurawski, Bogdan, Cortes, Paulo, Faustino, Catia, Vau, Nuno Sineiro, da Luz, Ricardo, Atduev, Vagif, Kirtbaya, Dmitry, Kopyltsov, Evgeny, Lykov, Aleksandr, Marat, Urmantsev, Orlov, Sergey, Penkov, Konstantin, Pirmagomedov, Albert, Semenov, Andrey, Varlamov, Sergey, Anguera, Georgia, Domenech, Montserrat, Girones, Regina, Gonzalez del Alba, Aranzazu, Milagro, Nuria Lainez, Luque, Raquel, Ortega, Esther Martínez, Mellado, Begoña, Méndez Vidal, María Jose, Fernandez, Esteban Nogales, Valderrama, Begoña Perez, Marín, Alvaro Pinto, Santander, Carmen, Huang, Yi-Hsiu, Su, Wen-Pin, Wu, Hung-Chan, Wu, WenJeng, Yu, Kai-Jie, Bilici, Ahmet, Goker, Erdem, Gumus, Mahmut, Karaoglu, Aziz, Kefeli, Umut, Köse, Fatih, Ozguroglu, Mustafa, Tural, Deniz, Turk, Haci, Yalcin, Suayib, Bondarenko, Igor, Khareba, Gennadii, Kidik, Yana, Lychkovskyy, Oleksandr, Sakalo, Valerii, Shevnia, Serghii, Stakhovskyy, Eduard, Bahl, Amit, Crabb, Simon, Powles, Thomas, Sankey, Peter, Sarwar, Mohammad, Benedetto, Pasquale, Burgess, Earle, Dawson, Nancy, Doshi, Gurjyot, Fleming, Mark, Maly, Joseph, Parikh, Mamta, Waterhouse, David, Siefker-Radtke, A.O., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Özgüroğlu, M., Valderrama, B.P., Laguerre, B., Basso, U., Triantos, S., Akapame, S., Kean, Y., Deprince, K., Mukhopadhyay, S., Loriot, Y.

Source: In Annals of Oncology January 2024 35(1):107-117

Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer

Authors: Bengio, Ruben, Cutuli, Hernan, Salinas, Jorge, Ameye, Filip, Joniau, Steven, Rodrigues da Rosa, Diogo, Martins da Trindade, Karine, Luz, Murilo Almeida, Bavaresco, Mario Henrique, de Paula, Adriano, Santiag, Jose, Wang, Shaogang, Ye, Dingwei, Boegemann, Martin, Roghmann, Florian, Heidrich, Albert, Hellmis, Eva, Faba, Óscar Rodriguez, Dominguez, Jose Luis, Mathieu, Romain, Colombel, Marc, Bladou, Franck, Artignan, Xavier, Vasdev, Nikhil, Shimpi, Rajendra, Guadalupi, Valentina, Tambaro, Rosa, Sirotova, Zuzana, Spada, Massimiliano, Necchi, Andrea, Nakatsu, Hiroomi, Kikuchi, Eiji, Shimizu, Nobuaki, Kanao, Kent, Sumitomo, Makoto, Naito, Yushi, Ham, Won Sik, Jung, Seung-Il, Ha, Hongkoo, Joo, Kwan Joong, Ku, Ja Hyeon, Seo, Ho Kyung, Yun, Seokjoong, Kolodziej, Anna, Lawinski, Janusz, Morris, David, Daneshmand, Siamak, Mian, Badar, Lee, Eugene, Catto, J.W.F., Tran, B., Rouprêt, M., Gschwend, J.E., Loriot, Y., Nishiyama, H., Redorta, J.P., Daneshmand, S., Hussain, S.A., Cutuli, H.J., Procopio, G., Guadalupi, V., Vasdev, N., Naini, V., Crow, L., Triantos, S., Baig, M., Steinberg, G.

Source: In Annals of Oncology January 2024 35(1):98-106

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

Authors: Blay, J.Y., Cropet, C., Mansard, S., Loriot, Y., De La Fouchardière, C., Haroche, J., Topart, D., Tougeron, D., You, B., Italiano, A., Le Brun-Ly, V., Ferrero, J.M., Penel, N., Fabbro, M., Troussard, X., Malka, D., Ray-Coquard, I., Leboulleux, S., Fléchon, A., Maubec, E., Charles, J., Dalle, S., Taieb, S., Garcia, G.C.T.E., Mandache, A.M., Colignon, N., Gavrel, M., Nowak, F., Hoog Labouret, N., Mahier Aït Oukhatar, C., Gomez-Roca, C.

Source: In ESMO Open December 2023 8(6)

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Authors: Rosenberg, J.E., Powles, T., Sonpavde, G.P., Loriot, Y., Duran, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Mamtani, R., Wu, C., Matsangou, M., Campbell, M., Petrylak, D.P.

Source: In Annals of Oncology November 2023 34(11):1047-1054

Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study

Authors: Bayle, A., Belcaid, L., Aldea, M., Vasseur, D., Peyraud, F., Nicotra, C., Geraud, A., Sakkal, M., Seknazi, L., Cerbone, L., Blanc-Durand, F., Hadoux, J., Mosele, F., Tagliamento, M., Bernard-Tessier, A., Verret, B., Smolenschi, C., Clodion, R., Auger, N., Romano, P.M., Gazzah, A., Camus, M.N., Micol, J., Caron, O., Hollebecque, A., Loriot, Y., Besse, B., Lacroix, L., Rouleau, E., Ponce, S., Soria, J.C., Barlesi, F., Andre, F., Italiano, A.

Source: In Annals of Oncology April 2023 34(4):389-396

French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)

Alternate Title: Recommandations du comité de cancérologie de l'Association Française d'Urologie - actualisation 2022-2024 : tumeurs de la vessie n'infiltrant pas le muscle (TVNIM) (French)

Authors: Neuzillet, Y., Pradère, B., Xylinas, E., Allory, Y., Audenet, F., Loriot, Y., Masson-Lecomte, A., Roumiguié, M., Seisen, T., Traxer, O., Leon, P., Roupret, M.

Source: In Progrès en Urologie November 2022 32(15):1102-1140

French AFU Cancer Committee Guidelines – Update 2022–2024: Upper urinary tract urothelial cancer (UTUC)

Alternate Title: Recommandations françaises du Comité de Cancerologie de l’AFU – Actualisation 2022–2024 : tumeurs de la voie excretrice urinaire superieure (TVES) (French)

Authors: Neuzillet, Y., Seisen, T., Traxer, O., Allory, Y., Audenet, F., Leon, P., Loriot, Y., Pradère, B., Roumiguié, M., Xylinas, E., Masson-Lecomte, A., Roupret, M.

Source: In Progrès en Urologie November 2022 32(15):1164-1194

French AFU Cancer Committee Guidelines – Update 2022–2024: Muscle-Invasive Bladder Cancer (MIBC)

Alternate Title: Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2022–2024 : tumeurs de la vessie infiltrant le muscle (TVIM) (French)

Authors: Neuzillet, Y., Audenet, F., Loriot, Y., Allory, Y., Masson-Lecomte, A., Leon, P., Pradère, B., Seisen, T., Traxer, O., Xylinas, E., Roumiguié, M., Roupret, M.

Source: In Progrès en Urologie November 2022 32(15):1141-1163

Recommandations du Comité de cancérologie de l'Association Française d'Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d'épirubicine et de BCG pour le traitement des tumeurs de la vessie n'infiltrant pas le muscle (TVNIM)

Authors: Leon, P., Saint, F., Audenet, F., Roumiguié, M., Allory, Y., Loriot, Y., Masson-Lecomte, A., Pradère, B., Seisen, T., Traxer, O., Xylinas, E., Roupret, M., Neuzillet, Y.

Source: Progrès en urologie. 32(5):299-311

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100160395412.0x000001&indx=1&recIds=ETOCvdc_100160395412.0x000001

Recommandations des Comités de cancérologie (CC-AFU) et d'infectiologie (CI-AFU) de l'Association française d'urologie pour la prise en charge effets indésirables et complications du BCG

Authors: Audenet, F., Sotto, A., Roumiguié, M., Allory, Y., Andrejak, C., Leon, P., Loriot, Y., Masson-Lecomte, A., Pradère, B., Seisen, T., Traxer, O., Xylinas, E., Bruyère, F., Roupret, M., Saint, F., Neuzillet, Y.

Source: Progrès en urologie. 32(3):165-176

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100157605581.0x000001&indx=1&recIds=ETOCvdc_100157605581.0x000001

Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients

Authors: Chen, J., Facchinetti, F., Braye, F., Yurchenko, A.A., Bigot, L., Ponce, S., Planchard, D., Gazzah, A., Nikolaev, S., Michiels, S., Vasseur, D., Lacroix, L., Tselikas, L., Nobre, C., Olaussen, K.A., Andre, F., Scoazec, J.Y., Barlesi, F., Soria, J.C., Loriot, Y., Besse, B., Friboulet, L.

Source: In Annals of Oncology April 2022 33(4):434-444

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Authors: Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B.P., Ravaud, A., Shariat, S.F., Szabados, B., van der Heijden, M.S., Gillessen, S.

Source: In Annals of Oncology March 2022 33(3):244-258

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Authors: Loriot, Y., Marabelle, A., Guégan, J.P., Danlos, F.X., Besse, B., Chaput, N., Massard, C., Planchard, D., Robert, C., Even, C., Khettab, M., Tselikas, L., Friboulet, L., André, F., Nafia, I., Le Loarer, F., Soria, J.C., Bessede, A., Italiano, A.

Source: In Annals of Oncology November 2021 32(11):1381-1390

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy

Authors: Bamias, A., Merseburger, A.S., Loriot, Y., James, N., Choy, E., Castellano, D., Lopez-Rios, F., Calabrò, F., Kramer, M., de Velasco, G., Zakopoulou, R., Tzannis, K., Sternberg, C.N.

Source: In ESMO Open June 2021 6(3)

Treatment of bladder cancer with immune checkpoints inhibitors

Authors: Grobet-Jeandin, É., Pinar, U., Loriot, Y., Roupret, M.

Source: Revue du praticien. 71(4):391-395

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN626797451&indx=1&recIds=ETOCRN626797451